• Pfizer's review of Lipitor begins | Adweek
Advertisement

• Pfizer's review of Lipitor begins

Advertisement

• Pfizer's review of Lipitor begins in June and remains undecided. The incumbent, Merkley + Partners, is eliminated in September, leaving three contenders: JWT, The Kaplan Thaler Group and mcgarrybowen. Billings are estimated at $60-80 million.

• In December 2004, the FDA demands that AstraZeneca pull ads for its anti-cholesterol drug Crestor, calling its safety claims "misleading." The following month, Crestor shifts from WPP's CommonHealth to Saatchi & Saatchi Consumer Healthcare. Spending from January through September this year falls to $120 million, down from $130 in the same period last year, per Nielsen Monitor-Plus.